News

Endpoints News1h
J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al
J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...
Endpoints News5h
Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na
Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in ...
Endpoints News8h
Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease
Topas Therapeutics reveals first data from celiac disease therapy study, showing promise in immune system retraining with ...
Endpoints News5h
In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges
Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...